Pharmaceutical - Johnson & Johnson, Boehringer Ingelheim, Respiratory and Pulmonary

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta


People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir


Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Pipeline anti-diabetic drugs could challenge market-leaders, says Datamonitor


Pipeline anti-diabetic drugs, including products from US drug major Eli Lilly (NYSE: LLY) and French…

albiglutideAmylinBoehringer IngelheimBydureonDiabetesdulaglutideEli LillyempagliflozinGlaxoSmithKlineInvokanaJohnson & JohnsonLantusNovo NordiskPharmaceuticalSanofiTresibaVictoza

Top drugmakers set up non-profit TransCelerate to speed pharma R&D


Some of the world's leading pharmaceutical companies have formed a non-profit organization to accelerate…

Abbott LaboratoriesAstraZenecaBiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGlaxoSmithKlineJohnson & JohnsonPfizerPharmaceuticalRegulationResearchRocheSanofiTransCelerate BioPharma

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested


The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Back to top